1300 304 460

Offer Amount (Min) $5,000,000
Offer Amount (Max) $8,000,000
Market Cap (Max) $31,434,924
EV on Listing (Max) $23,434,924
Issue Price $0.22
Open Date 7/11/2018
Bid Closing Date 12/11/2018*
Listing Date 7/12/2018^

* Peak's anticipated date of closing for new bids
^ Estimated date, subject to change without notice

EXECUTIVE SUMMARY

✔ The Company has developed a unique intuitive development platform which enables organisations to develop enterprise-scale applications to leverage blockchain technology
✔ Early establishment of highly credentialed client base and distribution partners
✔ Exceptional founding and management team, led by Michael Reh, a highly-regarded technology executive and Reinier Van Der Drift, a serial technology entrepreneur, who has had multiple million-dollar exits
✔ Operating in an addressable market estimated by Gartner to be US$3.1 Trillion by 2030
✔ One of the few blockchain technology companies that is generating operational revenues from Tier-1 clients
✔ Blockchain is widely predicted to be one of the most transformational technologies of our generation
✔ Supported by scalable footprint with an attractive valuation relative to ASX listed peers

BID NOW

COMPANY OVERVIEW

TYMLEZ’s vision is to be the gold standard provider of enterprise blockchain technology.

The Company has developed its own technology stack, enabling customers to develop blockchain applications. The platform is hyper-scalable, enterprise grade and solves the 2-speed IT problem that enterprises face when wanting to innovate on top of existing IT systems.

The development stack’s unique modelling environment allows secure and rapid development of sophisticated blockchain enabled enterprise applications. Visual modelling capabilities with Drag/Drop and Deploy functionality simplifies the development of smart contracts. This enables enterprise to develop blockchain applications in “minutes, rather than months”.

Built by an experienced team, the Company offers:

• A curated software suite that utilises a combination of open-source software & TYMLEZ IP

• An intuitive development and run-time platform which helps organisations develop new, blockchain applications (dApps)

• A platform that enables legacy systems to leverage the benefits that blockchain technology provide

• A visual drag-drop-deploy environment to compose applications, in minutes rather than months

BOARD & ADVISORS

Michael
Reh

Executive Director & CEO

Michael co-founded TYMLEZ in 2016

He is a long-time software executive having worked at Board Level for the world’s leading IT firms

Michael was Executive Vice President (VP) of the Business Information Technologies division and Chief Operations Officer of the Board in relation to technology and innovation at SAP (c.US$130B market cap) from 2001 - 2014

Following this, Michael was Executive VP and Global Head for Finacle at Infosys and most recently CEO and Board member at Edgeverve (8,000+ employees)

He has the ability to combine his technical expertise with his ability to understand customer business systems and processes and has worked in an international capacity for years building strong networks within the business information and technology space

Reinier
Van Der Drift

Executive Director & CMSO

Reinier co-founded TYMLEZ in 2016

Reinier is a serial technology entrepreneur, founding his first company in 1994

Reinier has been a leader in the ICT industry since 1984. He was the CEO and founder of Authasas which was acquired by Micro Focus in 2015

Reinier is presently a board member of the Hague Security Delta, which is a Dutch network of businesses, governments and institutions that work together on innovative security solutions and knowledge development

Reinier is also a thought leader and public advocate for the continued development of strong authentication technologies

He is a public representative of the security industry and participates in the media and open forums as an industry commentator

Rodney Hannington

Non-Executive Chairman

Rodney has international experience in Australia, China, Japan, South Korea and South East Asia, Middle East / Africa, Russia and Ukraine markets

He is a strategic and innovative marketer with deep experience in Asia, ASEAN & Australia and been a part of several company acquisitions and new product launches in China and Australia as a board member, consultant and employee

He is currently a non-executive director of Eagle Health Holdings Limited (ASX:EHH) and Non-Executive Chairman Lifespot Health Limited

Daniel
Dickens

Non-Executive Director

Daniel is a proven business leader, and currently retains the position of Chief Technology Officer for Cromwell Property Group – an ASX200 listed fund manager with over $10 billion in assets under management

At Cromwell, he has been instrumental in driving business adoption of cloud technologies and is regularly invited to speak at events such as Amazon’s AWS Summit and the Chief Information Security Officer Forum

Daniel has won multiple awards for his work from major software vendors Microsoft and Sage

Dr. Vishal
Sikka

Advisory Board Member

Vishal was an Executive Vice Chairman of Infosys Ltd and later became the CEO and MD of Infosys Ltd

Prior to this role, Vishal was a member of the Executive Board and the Global Managing Board of SAP AG where he led the development of the SAP HANA database management system product

Vishal is a computer scientist and holds a PhD from Stanford University

Richard
Kastelein

Advisory Board Member

Richard has extensive experience in the blockchain industry and was the founder of ‘Blockchain Industry’ and has written over 1,500 articles on blockchain technology

Richard holds an honorary PhD and is Chair Professor at the Jiangxi Ahead Institute of Software & Technology (Blockchain Facility)

Karl
Hoods

Advisory Board Member

Karl is currently Chief Digital & Information Officer of the British Department for Business, Energy, Energy and Industrial Strategy

He was previously the CIO of the Save the Children UK foundation where he investigated the use of blockchain solutions in the humanitarian space

BID NOW

CASE STUDY

Sales Channel: Direct Engagement
Licence Type: Development Licence
Licence Duration: Perpetual Basis
Status: The solution has been fully delivered to the customer and the Company shall provide ongoing Maintenance and Support Services

Customer Profile

Nico.Lab B.V. is a medical technology company based in The Netherlands that has developed StrokeViewer, which is an application that utilises artificial intelligence technology to assist with the analysis of medical imagery in stroke patients and clinical decision‑making. Strokeviewer is able to promptly generate a detailed biomarker report and allows remote image viewing on any device, thereby allowing direct sharing of imaging data between physicians and stroke care centres.

Business case

Nico.Lab B.V. needed to ensure that the exchange of data between its artificial intelligence software and the various hospitals, nurses and physicians was secure and compliant with the General Data Protection Regulation of the European Union (GDPR). Creating ‘trust’ in the data was also critical to allow physicians to confidently rely on the integrity of the data. Furthermore, maintaining an audit trail of all events and interactions between participants was not only necessary for Nico.Lab B.V. to satisfy the GDPR requirements but was also necessary in order to obtain insurance for the StrokeViewer product.

Solution offered

The Tymlez Platform was used to develop an application which enabled the secure transfer and encryption of data, thereby improving reliability and integrity of the data and maintaining patient data confidentiality. By allowing individual doctors across various hospitals to independently verify information received, the application was able to introduce trust and transparency into the process. Furthermore, a digital fingerprint is embedded in the individual analyses completed by the StrokeViewer’s artificial intelligence engine (which can be of up to 2000 brain scans per patient), thereby allowing users to identify the precise version of the artificial intelligence algorithm that was used to analyse the relevant imagery.

Benefits

✔ Enabled GDPR‑compliant and secure transportation of patient data, whereby such data is appropriately encrypted to restrict access to relevant parties

✔ Allowed patient imagery and analyses of such data to be digitally fingerprinted, thereby establishing integrity in the data stored

✔ Provided high speed processing and logging of data to ensure analyses conducted by the artificial intelligence engine remain within the 3 minute time limit

ASX COMPARABLES

* Numbers are indicative as at official admission to the ASX
^ Excludes R & D Tax Incentive Refund of $607,000 and Grant of $454,000

CAPITAL STRUCTURE

* Includes shares issued to the Lead Manager

MORE INFORMATION

Prospectus

Website

Click below to place your bid

BID NOW

• The issuer of the securities offered hereunder (Offer) is Tymlez Group Limited ACN 622 817 421, being a public company incorporated in Victoria, Australia (Company).
• Investors may access an electronic copy of the Replacement Prospectus pursuant to which the Offer is made and the accompanying Application Form on the Company’s website www.tymlez.com.
• The Offer is made in, and accompanied by a copy of the Company’s Replacement Prospectus.
• Investors should consider the Replacement Prospectus in its entirety in deciding whether to apply for securities offered under the Offer.
• Investors who want to apply for securities offered under the Offer will need to complete the Application Form accompanying the Replacement Prospectus.

The information described in this notice relates to the issue of new securities by the Issuer. A Prospectus for the issue of new securities is available and can be obtained from the Issuer’s website or by way of download from this website. The offer of securities will be made in, or accompanied by, a copy of the Prospectus. Nothing contained in this message and/or any attachment(s) constitutes a personal advice recommendation, solicitation or an offer to buy or sell any securities. Any recommendation or endorsement of this offer is general advice in nature and has not taken into account your personal circumstances or objectives. A person should consider the Prospectus in deciding whether to acquire the securities.

This notice does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. The Prospectus does not constitute an offer to sell, or a solicitation of any offer to buy, securities in the United States. The Prospectus has been prepared for publication in Australia.

Financial Services Guide